Virtual patent extension by cannibalization

Southern Economic Journal

Volumn 66, Issue 1, 1999, Pages 117-131

  Kamien, Morton I ^a   Zang, Israel ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033433693     PISSN: 00384038     EISSN: None     Source Type: Journal    
DOI: 10.2307/1060838     Document Type: Article

References (8)

1. Caves, R. E., M. D. Whinston, and M. A. Hurwitz. 1991. Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Papers on Economic Activity, pp. 1-66.
2. Comanor, W. S., and S. O. Schweitzer. 1995. Pharmaceutical. In The Structure of American Industry, edited by W. Adams and J. Brock. Englewood Cliffs, NJ: Prentice-Hall, pp. 177-96.
3. Frank, R. G., and D. S. Salkever. 1992. Pricing, patent loss and the market for pharmaceuticals. Southern Economic Journal 59:165-79.
4. Freudenheim, M. 1997. Prescription drug makers reconsider generics. The New York Times, 11 September.
5. Grabowski, H. G., and J. M. Vernon. 1992. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act. Journal of Law and Economics 35:331-50.
6. Morrow, D. J. 1998. Old drugs, new labels. The New York Times, 13 June.
7. Scherer, F. M. 1993. Pricing, profits, and technological progress in the pharmaceutical industry. Journal of Economic Perspectives 7:97-115.
8. Yang, C. 1994. The drug makers vs. the trust busters. Business Week, 5 September, pp. 67-8.